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Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder
characterized by deposition of fibrillar aggregates of 4R tau-protein in neurons and
glial cells of the brain. These deposits are a key neuropathological finding, allowing a
diagnosis of “definite PSP,” which is usually established post mortem. To date criteria
for clinical diagnosis of PSP in vivo do not include biomarkers of tau pathology.
For intervention trials, it is increasingly important to (i) establish biomarkers for an
early diagnosis and (ii) to develop biomarkers that correlate with disease progression
of PSP. [18F]-THK5351 is a novel PET-ligand that may afford in vivo visualization
and quantification of tau-related alterations. We investigated binding characteristics of
[18F]-THK5351 in patients with clinically diagnosed PSP and correlate tracer uptake
with clinical findings. Eleven patients (68.4 ± 7.4 year; N = 6 female) with probable
PSP according to current clinical criteria and nine healthy controls (71.7 ± 7.2 year;
N = 4 female) underwent [18F]-THK5351 PET scanning. Voxel-wise statistical parametric
comparison and volume-of-interest based quantification of standardized-uptake-values
(SUV) were conducted using the cerebellar cortex as reference region. We correlated
disease severity as measured with the help of the PSP Rating Scale (PSPRS)
as well as several other clinical parameters with the individual PET findings. By
voxel-wise mapping of [18F]-THK5351 uptake in the patient group we delineated
typical distribution patterns that fit to known tau topology for PSP post mortem.
Quantitative analysis indicated the strongest discrimination between PSP patients
and healthy controls based on tracer uptake in the midbrain (+35%; p = 3.01E-7;
Cohen’s d: 4.0), followed by the globus pallidus, frontal cortex, and medulla oblongata.
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Midbrain [18F]-THK5351 uptake correlated well with clinical severity as measured by
PSPRS (R = 0.66; p = 0.026). OCT and MRI delineated PSP patients from healthy
controls by use of established discrimination thresholds but only OCT did as well correlate
with clinical severity (R = 0.79; p = 0.024). Regional [18F]-THK5351 binding patterns
correlated well with the established post mortem distribution of lesions in PSP and with
clinical severity. The contribution of possible MAO-B binding to the [18F]-THK5351 signal
needs to be further evaluated, but nevertheless [18F]-THK5351 PET may still serve as
valuable biomarker for diagnosis of PSP.
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INTRODUCTION
Progressive supranuclear palsy (PSP) is a neurodegenerative
movement disorder from the group of atypical parkinsonism
manifesting with prominent hypokinesia, oculo-motor and
balance disturbances, and with behavioral changes (Stamelou
et al., 2010). Several clinical phenotypes of PSP have been
described. Patients with PSP-Richardson’s Syndrome (PSP-RS)
are considered to show an especially good clinic-pathological
correlation (Respondek and Hoglinger, 2016). While the initial
clinical presentation can resemble Parkinson’s disease, PSP has a
more malignant course, usually leading to death within a decade
after onset. Its pathophysiology is characterized by deposition
of fibrillar aggregates of 4-repeat tau protein in neurons and
glial cells in affected brain areas, i.e., basal ganglia, brainstem,
and cerebral cortex (Dickson et al., 2010). The presence of these
deposits is a key finding and leads to the neuropathological
diagnosis of “definite PSP,” usually established post mortem.
Current clinical criteria for diagnosis of possible or probable
PSP in living patients do not consider tau pathology (Litvan
et al., 1996). For future intervention trials, it is becoming
increasingly important to establish biomarkers that allow a
clear-cut ante mortem diagnosis of the underlying molecular
pathology. Furthermore, molecular markers are needed that can
serve as non-invasive markers of target engagement and disease
progression.
Molecular imaging of tau deposits by positron emission
tomography (PET) was mainly focused on Alzheimer’s disease,
the most common tauopathy. The repertoire of PET imaging
agents that target tau includes a carbon-11 labeled ligand
(Maruyama et al., 2013), and various [18F]-fluorinated
radiotracers, which present logistic advantages due to their
longer physical half-life (Okamura et al., 2013; Xia et al., 2013).
To date, the most promising [18F]-labeled tau ligands are the
pyrdioleindole [18F]-AV1451 (T807) and the arylquinoline
Abbreviations: HC, Healthy controls; MAPT, microtubule-associated protein
tau; MMSE, Mini-Mental State Examination; MNI, Montreal Neurological
Institute; MRI, magnetic resonance imaging; OCT, optical coherence tomography;
ONL/OPL, outer nuclear layer/outer plexiform layer; PET, positron emission
tomography; PSP, progressive supranuclear palsy; PSPRS, PSP rating scale; PSP-
RS, PSP-Richardson’s syndrome; PSP-PNFA, PSP-progressive non-fluent aphasia;
RNFL, retinal nerve fiber layer; SC, solvent containers; SEADL, Schwab and
England Activities of Daily Living scale; SPM, statistical parametric mapping;
SUVR, standard-uptake-value ratio; VOI, volume-of-interest.
[18F]-THK5351 (Harada et al., 2016), both of which have already
been investigated in Alzheimer’s disease.
Recent data suggest that by PET tau depositions can also
be discerned in atypical parkinsonian disorders (Coakeley and
Strafella, 2015), and in PSP in particular (Chiotis et al.,
2016; Hammes et al., 2016). Thus, systematic studies of PET
imaging should enable a better understanding of the roles
played by tau in the progression of atypical Parkinsonism
(Villemagne and Okamura, 2016). In Alzheimer’s disease, the
progression and spatial distribution of tau deposits, as known
from neuropathology, were recapitulated in PET studies using
[18F]-AV1451 (Schwarz et al., 2016). With the [18F]-FDDNP
tau ligand, proof of principle was obtained that PSP-specific tau
distribution patterns can be captured by PET (Kepe et al., 2013).
In vivo binding of this ligand in PSP brains, however, showed no
association with disease severity, which presumably is due to its
unfavorable binding affinity (Kuntner et al., 2009) and its lack of
specificity for tau aggregates (Tolboom et al., 2010).
Distinct quaternary structures of fibrillary tau in the various
tauopathies must be considered if radioligands are evaluated with
respect to the particular pathology targeted (Cairns et al., 2007).
Alternative splicing leads to 4-repeat tau in PSP as opposed to
3-repeat tau in Pick’s disease and balanced 3-/4-repeat tau in
Alzheimer’s disease (Murray et al., 2014). For example, the tau
aggregates of PSP are composed of straight filaments (Chin and
Goldman, 1996) to which the PET ligands available bind with
different affinities (Harada et al., 2016). Another issue is primary
age-related tau depositions, which are not considered pathologic
and are typically found in the medial temporal lobe in elderly
subjects (Schöll et al., 2016). Therefore, age-matched control
data are indispensable for the evaluation of tau-PET in patients
(Herholz, 2016). Importantly, very recent findings indicated an
off-target binding to monoamine oxidase B (MAO-B), which
emphasizes careful interpretation of in vivo results, especially
when alterations of MAO-B must be assumed (Ng et al., 2017).
The primary aim of this study was to characterize [18F]-
THK5351 binding in a group of patients with clinically diagnosed
PSP-RS with a broad range of severities, in comparison to a
group of age-matched neurologically healthy control subjects.
Our secondary aim was to correlate individual tracer uptake and
clinical findings on the PSP rating scale (PSPRS). Finally, we
sought to compare PET results with multimodal assessment by
optical coherence tomography (OCT) and magnetic resonance
imaging (MRI).
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MATERIALS AND METHODS
Clinical Evaluation
We enrolled 11 patients from the outpatient clinic for
neurodegenerative diseases at the Departments of Neurology,
Ludwig-Maximilians-Universität München and Technical
University of Munich, Munich, Germany with a diagnosis of
clinically probable PSP-RS according to current diagnostic
criteria (Litvan et al., 1996). Additionally, we enrolled a
single case with suspected PSP-progressive non-fluent aphasia
(PSP-PNFA) into the study. The control group consisted of
nine healthy and age-matched control subjects investigated at
Tohoku University School of Medicine in Sendai, Japan. Disease
severity was measured with the PSP Rating Scale (PSPRS; score
range 0–100, with higher numbers indicating higher severity)
(Golbe and Ohman-Strickland, 2007). Furthermore, functional
independence was measured using the Schwab and England
Activities of Daily Living scale (SEADL) and disease duration was
recorded. The cognitive state was assessed by the Mini-Mental
State Examination (MMSE). Written informed consent was
obtained by German and Japanese participants in accordance
with the Declaration of Helsinki. Retrospective analysis of data
had been approved by both local ethics committees (Medical




Automated production of [18F]-THK5351 was performed on
a Raytest R© SynChrom R&D single reactor synthesizer. The
radiochemical yield was 12 ± 4% (not decay-corrected, n = 10)
and radiochemical purity >99% at the end of the 84min
synthesis. A detailed description of the radiosynthesis is provided
in the Supplementary Material.
Image Acquisition and Reconstruction
Images in the patients were acquired using a GE Discovery
690 PET/CT scanner. A prior low-dose CT scan was performed
for attenuation correction. Dynamic 3-dimensional emission
recordings were acquired during an interval of 30–70min after
intravenous injection of 183± 4 MBq [18F]-THK5351. PET data
were reconstructed iteratively and binned into 5min frames for
visual assessment of possible head movement. The dynamic data
was evaluated to compare the previously-established 40–60min
p.i. window (Lockhart et al., 2016) for PSP target regions against
alternative 30–50 and 50–70min time windows.
Imaging in the control subjects was performed on
an Eminence STARGATE PET scanner with dynamic 3-
dimensional emission recordings during 0–90min, initiated
upon administration of 182 ± 3 MBq [18F]-THK5351; 30–50,
40–60, and 50–70min p.i. frames were iteratively reconstructed.
In order to adjust different resolution properties of the two PET-
scanners we aimed to perform harmonization after comparison
of 3-D Hoffmann brain phantom scans (Joshi et al., 2009). The
phantom analysis revealed that a final resolution of 8.0mm
(x/y-axis) and 9.0mm (z-axis) was achieved for both scanners
using the reconstruction parameters. Thus, no further adaption
was deemed necessary.
Anatomical MRI in patients was performed using a 3.0 Tesla
Magnetom (Signa HDxt, General Electric, Chicago, USA) with
a 8-element head coil. A sagittal 3D fast spoiled gradient echo
sequence (FSPGR) was acquired with the following imaging
parameters: field of view, 240× 240mm; spatial resolution, 1× 1
× 1mm; time of repetition, 6.616ms; time of echo, 3.150ms; flip
angle, 15; number of slices, 176.
Anatomical MRI in control subjects were performed using a
Signa 1.5-Tesla machine (General Electric). In T1-weighted MR
acquisition, a three-dimensional volumetric acquisition of a T1-
weighted gradient echo sequence produced a gapless series of thin
axial sections using a vascular TOF SPGR sequence (echo time/
repetition time, 2.4/50ms; flip angle, 45◦; acquisition matrix, 256
× 256; 1 excitation; field of view, 22 cm; slice thickness, 2.0mm).
Coregistration and Postprocessing
The PNEURO data processing pipeline of PMOD Version
3.5 (PMOD Technologies Ltd., Zurich, Switzerland) was used
for spatial normalization of all [18F]-THK5351 images to the
Montreal Neurological Institute (MNI) space.We first performed
co-registration of the individual MRI to a T1w template (Brendel
et al., 2015). Next, the 40–60min PET-images for all cases with
available MRI (N = 18) were scaled by global mean intensity,
and averaged for generation of a mixed PSP/healthy control
[18F]-THK5351 template in the MNI space. Subsequently, all
(N = 21) individual PET images were spatially normalized to
the [18F]-THK5351 template using the PMOD FUSION tool
(equal modality; nonlinear warping; 16 iterations; frequency
cutoff 3; regularization 1.0; no thresholding; 8mm transient input
smoothing). All co-registered images showed excellent spatial
agreement with visual inspection. The final transformation
matrices were applied to dynamic data and the other frame
intervals for congruent spatial normalization. Given that only
sporadic cerebellar tau depositions are reported in PSP when
ataxia is absent clinically (Kanazawa et al., 2009), a uniform
volume consisting of the cerebellar gray matter (114 cm3),
excluding the dentate nuclei, was used as the reference region for
image intensity normalization.
Voxel-Wise Analyses
Statistical parametric mapping (SPM) was performed using
SPM8 implemented in Matlab 7.12.0 (R2011a). PSP-RS patient
(N = 11) and healthy control (N = 9) groups were compared
by a voxel-wise two-tailed student’s t-test after 6mm Gaussian
smoothing. The contrast was performed after masking of extra-
cerebral structures, including caudo-dorsal segments of the
cerebellum (due to their propensity for edge artifacts), and with
exclusion of clusters of less than 20 voxels. Voxels surviving
p < 0.05 after correction for multiple comparisons (false
discovery rate, FDR) were considered significant. Z-score maps
for individual patient/control contrasts were generated using
PNEURO after having first calculated a normative database
(mean/standard deviation, SD), and upon 6mm Gaussian
smoothing. Maps showing Z-scores > 3 were visually displayed
using an image overlay tool implemented in Matlab.
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Semiquantitative PET Analyses
For semiquantitative analyses, volumes-of-interest (VOIs)
were defined in T-score maps deriving from SPM analyses
superimposed on the individual MRIs for anatomical validation.
The 3-dimensional assignment of “hot” voxel clusters to VOIs
was performed with a T-score threshold of >3.56 (≈SPM
p < 0.05, FDR). Predefined Hammers atlas VOIs (Hammers
et al., 2003) were additionally applied for brainstem, midbrain
(extracted from brainstem), and bilateral precentral gyri,
superior and inferior frontal gyri, putamen, globus pallidus, and
substantia nigra. Mean standard-uptake-value ratios relative
to cerebellum (SUVRCBL) were calculated for each VOI in all
subjects.
Multimodal Analyses
Optical Coherence Tomography and Intraretinal Layer
Segmentation
OCT examination was performed using a SD-OCT aparatus
(Spectralis, Heidelberg Engineering, Heidelberg, Germany). The
OCT protocol included a peripapillary ring scan for measuring
peripapillary retinal nerve fiber layer (pRNFL) (12◦, 3.4mm)
around the optic nerve with a minimum of 50 automatic
real time repetitions, respecting OSCAR-IB criteria (Schippling
et al., 2015), and a macular scan consisting of 25 vertical scans
centered on the fovea. The relevant OCT parameters global
pRNFL, total macular volume, and all intra-retinal layer volumes
were obtained with the help of macular segmentation. Macular
segmentation was performed with Spectralis Viewing Module
V. 6.0.9.0 provided by Heidelberg Engineering. As described
previously (Balk et al., 2014), the mean volume within the
perifoveal rim was calculated for the pRNFL (macular retinal
nerve fiber layer), mGCL (macular ganglion cells layer), mIPL
(macular inner plexiform layer), mINL (macular inner nuclear
layer), mOPL (macular outer plexiform layer), and mONL
(macular outer nuclear layer). We calculated the ratio ONL
central/mean (OPL nasal; OPL temporal) based on macular
volume data (Albrecht et al., 2012). OCT was intended to be
performed in patients but not in controls of the study.
Magnetic Resonance Imaging
In accordance with a prior study assessing midbrain atrophy in
patients with PSP (Cosottini et al., 2007), we determined the
ratio of the midbrain cross-sectional area scaled by the pons
area (Amidbrain/Apons). All measurements were performed using
the Hermes Viewer (Hermes Medical Solutions AB, Stockholm,
Sweden) on mid-sagittal images of T1w 3-dimensional sequences
with an isotropic voxel resolution of 1 × 1 × 1mm3. A mid-
sagittal plane of the brain volume passing through the middle
of the interpeduncular fossa, the middle of the aqueduct, and
the falx cerebri was chosen (each determined on axial images).
The midbrain area was determined by tracing the contour of the
midbrain down to a line parallel to the hypothetic conjunction
between the genu and splenium of the corpus callosum touching
the superior part of the pons. For the determination of the pons
midsagittal area, we used the region underneath, extending from
the lower bound of the midbrain area down to a parallel line
touching the inferior border of the pons.
Statistics
Demographic and semiquantitative PET results in different
target VOIs were compared between PSP patient and control
groups using a two-tailed Student’s t-test. Effect sizes for
the discrimination between PSP and healthy controls were
calculated as Cohen’s d. Multimodal assessments by OCT and
MRI were compared against published discrimination thresholds
for PSP or neurodegeneration on a single patient level, and
are reported descriptively in relation to reported standard
deviations of findings in healthy controls. Correlation analyses
between PET SUVRCBL in target VOIs and clinical parameters
(PSPRS, SEADL, disease duration), as well as inter-modality
correlations were performed using either Pearson’s coefficient of
correlation (R), or Spearman rank correlation (Rs) as deemed
appropriate after prior testing for normal distribution of data
by Kolmogorov-Smirnov-Test. The single PSP-PNFA case was
evaluated descriptively.
RESULTS
Demographic and Clinical Data
PSP-RS patients and healthy controls were matched for age and
education, as detailed in Table 1 that also shows that cognitive
performance tended to be lower in the PSP group by about
one MMSE point (p = 0.052), but was still in the range that
is not regarded indicative of dementia. In the PSP-RS group,
a wide range of clinical severity (PSPRS range 19–44, SEADL
range 50–90) and of disease duration (7–60 months) was present.
The suspected PSP-PNFA case was a female aged 65 years
with PSPRS of 10, SEADL of 90, and disease duration of 22
months.
[18F]-THK5351 Pet Imaging
Tracer Kinetics and Time Window
Higher [18F]-THK5351 retention was evident on visual
inspection in the midbrain of the PSP-RS patient group when
compared to controls (Figures 1A,B). Dynamic imaging in all
subjects, controls as well as patients, confirmed highest stability
in midbrain SUV for times exceeding 50min p.i. (Figure 1C;
slope increase: 3.1% for 50–70min p.i. vs. 9.5% for 40–60min
TABLE 1 | Demographics and Clinical Presentation.
PSP (N = 11) Healthy controls (N = 9)
Age (y) 68.4 ± 7.4 71.6 ± 6.6
Gender (m/f) 5/6 5/4
Education (y) 13.2 ± 3.2 12.9 ± 2.5
MMSE (median, range) 27, 25–29 28, 26–30
PSPRS (median, range) 30, 19–44 n/t
SEADL (median, range) 60, 50–90 n/t
Disease Duration (mo) 36 ± 19 n/a
Y, years; m, male; f, female; n/a, non applicable; n/t, non tested; MMSE, mini-mental state
examination; PSPRS, progressive supranuclear palsy rating scale; SEADL, Schwab and
England Activities of Daily Living scale; mo, months.
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FIGURE 1 | High midbrain uptake in sagittal slices allows visual discrimination of the PSP patient group (A) from the healthy control group (HC) (B). Axial slices
through the brain indicate high background binding in the basal ganglia and brainstem regions of HC, but further elevation in regions with known tau deposition in PSP
vs. HC (midbrain, dentate nucleus, globus pallidus, frontal cortex). Images represent group averages. (C) Dynamic imaging indicates stable kinetics ≥ 50min p.i. as
illustrated by a persistently higher time-activity-curve (ratio), deriving from PSP patients in contrast to the mean for the healthy control group (mean ± SD). Data points
represent an average of all counts in a defined time frame.
p.i. window). We selected the 50–70min post injection (p.i.)
window for further static analyses.
Voxel-Wise PET Analyses
SPM analysis to investigate voxel-wise differences between
clinical PSP-RS patient and healthy control groups showed
significant clusters of elevated [18F]-THK5351 PET signal in
the midbrain (412 voxels), bilateral globus pallidus (436 voxels),
bilateral frontal cortex (2258 voxels), and the medulla oblongata
(50 voxels) in patients vs. controls (Figure 2A; threshold:
p < 0.05, FDR corrected).
VOI-Based PET Analyses
Semi-quantitative analysis indicated the strongest discrimination
between PSP-RS and healthy controls for [18F]-THK5351 uptake
in themidbrain (+35%; p= 3.01E-7; Cohen’s d= 4.0; Figure 2B),
followed by the frontal cortex (+28%; p = 1.73E-7; Cohen’s
d = 3.7), globus pallidus (+24%; p = 3.84E-7; Cohen’s d = 3.6),
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and medulla oblongata (+20%; p = 1.01E-5; Cohen’s d = 2.7)
(Table 2, Supplementary Figure 1A). Results obtained using the
predefined atlas VOIs mirrored the voxelwise results, albeit
with lower effect size (Supplementary Table 1). The range of
[18F]-THK5351 uptake values in the midbrain of patients did
not overlap with control values, either for SPM defined or for
predefined atlas VOIs.
We tested the correlation of clinical severity scores with the
[18F]-THK5351 PET SUVR from the four target regions in order
to explore their possible associations with estimated regional
quantification in vivo. Figure 3A illustrates the significant
positive correlation between clinical severity (measured with
PSPRS) and midbrain [18F]-THK5351 uptake (R = 0.66,
p = 0.026), which was the brain region with the largest effect
size with respect to tracer uptake. [18F]-THK5351 PET binding
in the frontal cortex, globus pallidus, or medulla oblongata did
not significantly correlate with PSPRS scores (see Supplementary
Figure 1B). Significant correlations or trends were not found
between SEADL scores or disease duration and [18F]-THK5351
PET signal in any brain region. Importantly, no correlations or
trends between age and [18F]-THK5351 binding in target regions
were observed in controls (exemplary midbrain: R = 0.09,
p= 0.767; Figure 3B).
Individual Z-score maps indicated the ability of capturing the
alterations of [18F]-THK5351 PET signal vs. healthy controls
on the single patient level. Here, the correlation of clinical
severity with midbrain binding was further substantiated, which
is exemplified in individual cases with low and high PSPRS
scores, respectively (compare Figures 3C,D). Notably binding
in the frontal cortex did not follow the clinical severity and
was sometimes even higher in cases with a low PSPRS when
compared to cases with high PSPRS (compare Figures 3C,D).
This was also reflected by the correlation between PSPRS
and frontal cortical [18F]-THK5351 PET signal (R = −0.13,
p= 0.707).
The single case of suspected PSP-PNFA (PSPRS 10 at time
of PET scan) had a rather different distribution pattern,
which was characterized by accumulation of the tracer
predominantly in the frontal cortex and only minor subcortical
binding (Figures 4A,B). Quantitatively, the (by far) highest
[18F]-THK5351 PET signal was in cortex (SUVR 2.01 vs. 1.51 ±
0.09 in the remaining patients), with little evidence of elevated
FIGURE 2 | (A) Regional statistical parametric mapping of tau depositions in the whole cohort of PSP patients (N = 11) in contrast to healthy controls (HC; N = 9).
Two-tailed t-test; significance threshold: p < 0.05 (FDR-corrected); k > 20 voxel. T-score maps are projected upon an in-house MRI template. (B) Quantitative single
patient PET values from the resulting midbrain VOI indicating a high contrast without overlap between PSP and HC.
TABLE 2 | [18F]-THK5351 PET estimates in PSP-RS and HC.
Brain region SPM (voxels) PSP-RS (SUVRCBL) HC (SUVRCBL) Difference (%) Effect size (d)
Midbrain 412 3.35 ± 0.31 2.49 ± 0.12 +35 ± 12 4.0
Frontal cortex 2258 1.51 ± 0.09 1.18 ± 0.09 +28 ± 7 3.7
Globus pallidus 436 3.02 ± 0.19 2.44 ± 0.14 +24 ± 8 3.6
Medulla oblongata 50 2.76 ± 0.16 2.30 ± 0.18 +20 ± 7 2.7
SPM- and VOI-based results of [18F]-THK5351 PET in groups of PSP patients and HC. HC, Healthy controls; PSP-RS, progressive supranuclear palsy Richardson’s Syndrome; SUVR,
standardized-uptake-value-ratios; CBL, cerebellum; SPM, Statistical parametric mapping; VOI, volume-of-interest.
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FIGURE 3 | Positive correlation between quantitative [18F]-THK5351 PET results in midbrain with the clinical ratings by PSPRS (A). Age was not correlated with
tau-PET uptake in target regions as tested in healthy controls (HC), exemplified for the midbrain (B). Examples of individual Z-score maps in a PSP-RS patient with low
clinical severity (C; PSPRS 19) and only minor uptake in midbrain (highlighted by white arrow) in contrast to a PSP-RS patient with comparatively higher clinical
severity (D; PSPRS 39) and strong tau accumulation in midbrain (highlighted by white arrow).
midbrain [18F]-THK5351 accumulation (Figure 4C; SUVR 2.86
vs. 3.35 ± 0.31 in remaining patients vs. 2.49 ± 0.12 in healthy
controls). Clinical follow-up 1 year after the PET scan indicated
a dramatic disease progression (PSPRS: 38), and resulted in a
definitive diagnosis of PSP-PNFA.
Correlation with Other Techniques: Optical
Coherence Tomography and Magnetic
Resonance Imaging
For multimodal comparison of [18F]-THK5351 PET and for
more detailed classification of the patient group, we undertook
assessment by OCT (in 8/11 PSP-RS patients) and MRI (9/11)
in comparison with findings in normal subjects in the literature.
OCT was not feasible in three patients due to impaired fixation.
Two patients refused MRI.
OCT revealed ONL/OPL ratios in a range of 2.2 SD below
the published discrimination threshold (Albrecht et al., 2012)
(vs. Parkinson’s disease data) for confirmation of PSP in all
eight patients. Seven of eight patients ranged clearly below the
threshold and one at borderline value (Figure 5A). ONL/OPL
values correlated inversely with clinical severity by PSPRS
(R = 0.79; p = 0.024). The midbrain-to-pons ratio calculated
from MRI was decreased by as much as 2 SD (Cosottini et al.,
2007) in all PSP patients, although there was no significant
correlation between MRI findings and clinical symptom severity
(Figure 5B).
ONL/OPL ratios indicated a trend toward negative correlation
with the [18F]-THK5351 PET signal in the midbrain (R = 0.51;
p = 0.195; Figure 5C), whereas the midbrain-to-pons ratio
deriving from MRI did not show a clear association with [18F]-
THK5351 PET binding (R=−0.12; p= 0.761; Figure 5D).
DISCUSSION
We present the first dedicated [18F]-THK5351 PET study in
a clinically well-characterized group of PSP-RS patients and
demonstrate that enhanced in vivo tracer uptake in the midbrain
clearly discriminates PSP-RS patients from age-matched HCs.
We also found, on voxel-wise analysis, that in living patients
there are patterns of tracer uptake distribution that parallel
the post mortem findings of lesions in PSP-RS. This suggests
the suitability of the method for diagnostic and maybe for
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FIGURE 4 | Sagittal and axial slices are presented in analogy to Figure 1, and therefore afford a visual comparison of PSP-PNFA, PSP-RS, and HC (A). The most
impressive finding was the strong uptake in the frontal cortex in PSP-PNFA, which was as well very prominent in voxel-wise individual Z-score analysis vs. the HC
group (B). Quantitative VOI-based analysis indicated a midbrain signal at the bottom of PSP-RS cases, but the (by far) highest [18F]-THK5351 PET signal in the frontal
cortex frontal of all studied cases (C). Clinical severity was low at the time of the PET scan (PSPRS: 10), but had substantially increased at 1 year follow-up
(PSPRS: 38).
disease monitoring purposes. Furthermore, our data indicate a
correlation between midbrain [18F]-THK5351 PET signal and
clinical severity.
In the entire group of patients with a clinical diagnosis
of suspected PSP, the mean [18F]-THK5351 PET signal was
significantly elevated in midbrain, bilateral globus pallidus,
bilateral frontal cortex, and medulla oblongata. This distribution
pattern is an excellent match to the topology of tau deposition
known from histological examination post mortem (Williams
et al., 2007). The [18F]-THK5351 PET signal in the dentate
nucleus as another tau accumulating region in PSP was also
elevated visually but did not survive the significance threshold
for multiple comparisons, probably due to the relatively
lower pathology in this region and due to the small size
suffering from larger partial volume effects. Nonetheless, possible
contamination of the cerebellar cortex reference region by spill-
over is a potential confound in individuals with high tau
deposition in the dentate nucleus, as is typical in cerebellar
variants of PSP (Kanazawa et al., 2009). The range of clinical
severity in the patients (PSPRS 31 ± 8, range 19–44), is a
strength of the present study, as it represents a clinically less
affected group than the PSP patients of a previous report with
the alternative PET tracer [18F]-FDDNP (PSPRS 42.4 ± 9.5)
(Kepe et al., 2013). Thus, [18F]-THK5351 discriminates PSP
patients from controls even at earlier disease-stages, yet the
exact detection threshold can only be defined in a larger cohort.
Interestingly, we obtained an initial impression of the fitness of
this tracer for molecular imaging of non-RS PSP; our single case
of the rare disease entity PSP-PNFA showed slightly elevated
midbrain tracer accumulation, and very high [18F]-THK5351
PET signal in cortex (Figure 4). This finding corresponds well
with the clinical course of this rare disease subtype (5% of PSP-
tau), manifesting with non-fluent aphasia some years before
the onset of typical PSP motor symptoms. Our findings are
further supported by the documented gray matter atrophy in
the same prefrontal regions to volumetric MRI examination
of four PSP-PNFA cases (Rohrer et al., 2010). Although we
cannot draw strong conclusions from a single case, we have
preliminary evidence that the heterogeneity of PSP variants
can be depicted by [18F]-THK5351 PET. The main findings
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FIGURE 5 | Resulting values of OCT (A) and MRI (B) are illustrated for each examined PSP patient together with the published discrimination threshold against
healthy controls (red line). Linear correlations between clinical severity (PSPRS) and OCT/MRI are indicated by black lines. Inter-modality correlations are shown for
OCT and [18F]-THK5351 PET (C) as well as for MRI and [18F]-THK5351 PET (D) and indicated by black lines.
of the study are encouraging for the use of [18F]-THK5351
PET for PSP diagnosis in atypical or clinically ambiguous
cases.
We found a significant correlation between the intensity of
the [18F]-THK5351 midbrain signal and disease severity, as
estimated by PSPRS (Figure 3A). This finding emphasizes the
clinical potential of this biomarker through imaging of the
symptom-related disease related pathology in individual patients.
It reflects on the predominance of core symptoms of PSP-RS for
disease severity caused by local tau pathology in the midbrain
(Golbe and Ohman-Strickland, 2007). Absent correlations for
other brain regions could be due to insufficient statistical
power, but might also reflect region-specific associations with
distinct symptoms, perhaps better investigated in a larger
group of patients. Importantly, very recent findings of MAO-
B interaction of [18F]-THK5351 have to be taken into account
when interpreting the current results (Ng et al., 2017). We note
that further studies need to address which fraction of [18F]-
THK5351 binding in the brain of PSP patients is caused by
specific tau deposit binding and which fraction is related to
off-target MAO-B binding, which might be as well-elevated
due to concomitant neuroinflammation (Zimmer et al., 2014).
Nonetheless the correlation of tracer signal with clinical severity
at least assures us about well-capturing the disease stage.
Investigations of [18F]-THK5351 PET as a disease biomarker
must accommodate possible normal age-dependent changes
in healthy brain. We found no correlation between [18F]-
THK5351 midbrain binding and age in our group of healthy
controls (Figure 3B). This is in agreement with an earlier
finding for the tau binding component of [18F]-AV1451 (Schöll
et al., 2016). The slightly greater age of our control group
supports the unambiguous attribution of group differences to
tau pathology in the PSP group. A preliminary comparison of
tau-PET with other modalities is provided in the Supplementary
Material.
Off-target binding as alreadymentioned abovemay contribute
to the uptake patterns of newly developed tau-ligands. In
particular, the pyridoindole ligand [18F]-AV1451 and the
arylquinoline ligand [18F]-THK5351 both have unexpectedly
high SUVR in the basal ganglia and brainstem structures of
healthy volunteers (Betthauser et al., 2016), which is likely
related to off-target binding (Marquié et al., 2015). In our recent
analysis, we found that off-target binding to neuromelanin or
MAO-B can explain [18F]-THK5351 off-target retention in the
midbrain. We are unaware of any grounds to expect important
differences in neuromelanin binding in the substantia nigra
of Caucasians as opposed to Asians. Furthermore, in PSP,
neuromelanin- containing neurons of the substantia nigra are
undergoing degeneration as part of the natural course of the
disease. As such, this non-specific binding component would
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be expected to decrease in PSP. That we observe the opposite
is evidence that we are detecting a real increase caused by tau
pathology. Interestingly, reduced off-target binding of [18F]-
AV1451 in the substantia nigra reveals the degeneration of
pigmented dopamine neurons in Parkinson’s disease patients
(Hansen et al., 2016). Thus, it is crucial to establish the
regional specificity of tau-tracers for tau deposition in PSP
and other neurodegenerative diseases. Another off-target of
[18F]-THK5351 is considered to be MAO-B (Ng et al., 2017).
In the autoradiography of healthy control brain, we observed
[18F]-THK5351 off-target binding in the basal ganglia and
MAO-B inhibitors can completely block these [18F]-THK5351
binding (manuscript in preparation). As a neuroinflammatory
component of taupathies is well-known we acknowledge that
our elevated PET signal in PSP patients may be a composite
of tau and MAO-B binding. Compared to [18F]-AV1451,
no off-target [18F]-THK5351 binding exists in the choroid
plexus.
In a recent [18F]-AV1451 study the cerebral signal was higher
in PSP patients compared to healthy controls, which matched
the known disease topology and clinical severity (Whitwell et al.,
2016), as in the present [18F]-THK5351 study. However, two
other recent [18F]-AV1451 studies revealed significantly elevated
SUVR in the basal ganglia of PSP patients when compared to
healthy controls, without clear relation to the expected disease
pathology, and not correlating with clinical severity (Cho et al.,
2016; Smith et al., 2016a). Notably, PET examination with this
tracer clearly distinguishes PSP from Parkinson’s disease and
Alzheimer’s disease patients (Cho et al., 2016; Whitwell et al.,
2016). However, autoradiography in one of these studies did not
confirm the specific binding of [18F]-AV1451 to tau aggregates.
Another in vitro study indicated low displaceable binding to PSP
tau in brain sections, with no correlation between tracer binding
in vitro and quantitative tau load (Sander et al., 2016). On the
other hand, [18F]-THK5351 had specific binding to PSP tissue
examined by autoradiography post mortem, which matched tau
deposition to immunohistochemistry (Ishiki et al., 2016). Present
data are in line with the in vitro findings, and generally support
the fitness of [18F]-THK5351 PET for the sensitive detection of
tau deposits, with the caveat that high background in controls
most likely reflects an off-target binding component.
In line with the present results with the arylquinoline ligand
[18F]-THK5351, others have reported elevated PET signal with
this tracer in a single PSP case (Chiotis et al., 2016). Another
report did not observe specific autoradiography binding in tissue
of a single PSP patient for both tritiated tracers (Smith et al.,
2016b), which might be related to methodological factors in
vitro. Specific binding to 4R tau in vitro would be influenced by
the particular tracer concentration and washing procedures, for
example. Earlier findings in patients with corticobasal syndrome
are discussed in the Supplementary Material.
Among the limitations of the current investigation we note the
lack of histopathological validation which reflects the moderate
clinical severity within our patients, all of whom are alive at
the time of writing. However, the present results have face
validity given the high agreement between [18F]-THK5351 PET
findings and known topology of tau distribution. We further
note that data from PSP patients and healthy controls were
derived from centers using different PET scanners, albeit of
similar performance. Confounds due to minor differences in PET
resolution and partial volume effects, as well as effects deriving
from differing subject ethnicity, cannot be fully excluded. We
acknowledge also the small sample size of PSP patients imaged
by [18F]-THK5351 PET. Amyloid status was not assessed for
patients (8/9 of HC had an amyloid scan available which
was negative in all cases), which limits the interpretation
of [18F]-THK5351 PET in the unlikely event of coexisting
Alzheimer’s disease pathology, although this is not expected due
to excellent specificity of the NINDS-SPSP diagnostic criteria
for the diagnosis of PSP (Respondek et al., 2014). Despite
these considerations, we find the method proves robust for the
intended discrimination, and suggest that the present results
justify to initiate a larger multicenter investigation of this rare
disease.
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